Cargando…

Risk Factors and Prognostic Impact of Postoperative Complications in Patients with Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy

Background: Neoadjuvant chemotherapy is important to improve the prognosis of patients with advanced gastric cancer. However, it may result in postoperative complications (POCs). The aim of this study is to evaluate risk factors and prognostic impact of POCs in patients receiving neoadjuvant chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Hong, Xu, Li, Yin, Songcheng, Jiang, Jianlong, Hong, Chunhong, He, Yulong, Zhang, Changhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498105/ https://www.ncbi.nlm.nih.gov/pubmed/36135080 http://dx.doi.org/10.3390/curroncol29090511

Ejemplares similares

Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer
por: Li, Yang, et al.
Publicado: (2018)

Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers: A systematic review and meta-analysis
por: Luo, Huiyu, et al.
Publicado: (2018)

Comparison of postoperative complications in advanced head and neck cancer patients receiving neoadjuvant chemotherapy followed by surgery versus surgery alone
por: Joshi, Poonam, et al.
Publicado: (2015)

The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy
por: Sakin, Abdullah, et al.
Publicado: (2021)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019)

Prognostic value of CEA and CA19-9 in patients with local advanced rectal cancer receiving neoadjuvant chemoradiotherapy, radical surgery and postoperative chemotherapy
por: Shan, Jingjing, et al.
Publicado: (2021)

Poor Prognosis and Therapeutic Responses in LILRB1-Expressing M2 Macrophages-Enriched Gastric Cancer Patients
por: Zhang, Yawei, et al.
Publicado: (2021)

The prognostic impact of pretreatment anemia in patients with gastric cancer and nonhypoalbuminemia undergoing curative resection: a retrospective study
por: Jiang, Jianlong, et al.
Publicado: (2021)

In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator
por: Chen, Li, et al.
Publicado: (2021)

The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy
por: Iwase, Toshiaki, et al.
Publicado: (2021)

Identification of a Two-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival in Diffuse-Type Gastric Cancer
por: Chen, Songyao, et al.
Publicado: (2022)

AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy
por: Ahmed, Syed Minhaj Uddin, et al.
Publicado: (2019)

The influence of neoadjuvant chemotherapy on gastric cancer patients’ postoperative infectious complications: What is the negative role played by the intestinal barrier dysfunction?
por: Wei, Zhiliang, et al.
Publicado: (2017)

Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy
por: Jiang, Qi, et al.
Publicado: (2022)

Abstract QS24: Outcomes in Patients Receiving Neoadjuvant Chemotherapy Undergoing Immediate Breast Reconstruction: Effect of Timing and Postoperative Complications
por: Venutolo, Christopher J., et al.
Publicado: (2018)

Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy
por: Xu, Yaqian, et al.
Publicado: (2020)

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Meattini, Icro, et al.
Publicado: (2014)

A Retrospective Study of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
por: Wang, Yajing, et al.
Publicado: (2020)

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
por: Cao, Maria D, et al.
Publicado: (2012)

Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer
por: Gan, Xuejun, et al.
Publicado: (2023)

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis
por: Zhu, Youqi, et al.
Publicado: (2023)

Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis
por: Wu, Pei, et al.
Publicado: (2018)

Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
por: Yin, Xin, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer
por: Tong, Xie, et al.
Publicado: (2023)

The Prognostic Value of Lymph Node Ratio after Neoadjuvant Chemotherapy in Patients with Locally Advanced Gastric Adenocarcinoma
por: Zhu, Kankai, et al.
Publicado: (2021)

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
por: Duan, Xiao-Peng, et al.
Publicado: (2023)

Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer
por: Li, Jing, et al.
Publicado: (2016)

FN1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers
por: Wang, Han, et al.
Publicado: (2022)

Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis
por: Xue, Ling Bo, et al.
Publicado: (2019)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
por: Li, Zi-Yu, et al.
Publicado: (2011)

Prognostic Model of D2 Radical Gastrectomy Combined with Neoadjuvant Chemotherapy for Gastric Cancer
por: Wang, Guangjun, et al.
Publicado: (2023)

Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer
por: CUI, HAI-BIN, et al.
Publicado: (2014)

Clinical Value of PLR, MLR, and NWR in Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
por: He, Baojun, et al.
Publicado: (2022)

Postoperative complications after esophagectomy for cancer, neoadjuvant chemoradiotherapy compared to neoadjuvant chemotherapy: A single institutional cohort study
por: Ólafsdóttir, Halla Sif, et al.
Publicado: (2023)

Prognostic factors associated with locally advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by surgical resection
por: Sun, Yongkun, et al.
Publicado: (2017)

Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer
por: Palmela, Carolina, et al.
Publicado: (2017)

Neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: our experience in the elderly
por: Bugiantella, W, et al.
Publicado: (2009)

Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease
por: Li, Jing, et al.
Publicado: (2017)

PUM1 Promotes Tumor Progression by Activating DEPTOR‐Meditated Glycolysis in Gastric Cancer
por: Yin, Songcheng, et al.
Publicado: (2023)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e402vkkt08mcei5icr9o2sa3t5